Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market

Growth Will be Driven by Drugs from Eli Lilly/Daiichi Sankyo, AstraZeneca, and Schering-Plough, According to a New Report from Decision Resources

WALTHAM, Mass., March 24 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the patent expiries by 2012 of the two sales-leading therapies, new product launches will drive an increase of $4.6 billion in the overall coronary heart disease market by 2017.

The new Pharmacor report entitled Coronary Heart Disease finds that the market to treat the disease will grow from $14.8 billion in 2007 to $19.4 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Growth will be driven by the launches of Eli Lilly/Daiichi Sankyo’s Efient/Effient, AstraZeneca’s Brilinta and Schering-Plough’s SCH-530348 as well as the introduction of two new CETP inhibitors from Roche/Japan Tobacco and Merck.

Despite the patent expiry of the two sales-leading coronary heart disease therapies by 2012 — Sanofi-Aventis/Bristol-Myers Squibb’s Plavix/Iscover and Pfizer’s Lipitor — the market entry of fixed-dose combinations with agents such as Abbott’s Tricor/TriLipix, Solvay’s Lipanthyl and Abbott’s Niaspan will also offset the negative impact of generic erosion, according to the report.

“Cardiologists’ approach to coronary heart disease therapy has experienced a remarkable international convergence as optimal drug treatment for post-myocardial infarction — the condition that accounts for more than 70 percent of coronary heart disease market sales — now consists of two antiplatelet agents, including aspirin, a statin, an ACE inhibitor and a beta blocker,” said Decision Resources Therapeutic Area Director Nikhil Mehta. “Multidrug therapy has also become routine in the treatment of stable angina. The arrival of novel agents will be welcomed by clinicians, particularly for high-risk patients, but some of these therapies could face market access and compliance hurdles.”

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com

SOURCE Decision Resources